Calithera Biosciences (NASDAQ:CALA) Rating Reconfirmed

In analysts note revealed to clients on Tuesday, 28 March, Calithera Biosciences (NASDAQ:CALA) stock Buy was reconfirmed by H.C. Wainwright. They currently have a $14.0 price target on the stock. H.C. Wainwright’s price target indicates a potential upside of 31.46 % from the company’s current price.

NASDAQ:CALA is at the moment trading 2.40% higher at $10.65 as of 12:00 AM New York time. Calithera Biosciences’s stock is 0% in the past 200 days. It has underperformed the Standard & Poor’s 500 index, which has added 10.69% in the same time.

Institutional Ownership

Franklin Street Advisors Inc Nc had the most significant stake with ownership of 100,000 shares as of q2 2015 for 0.06% of the fund’s portfolio. Sabby Management Llc is another bull as the investment professional who is possessing 324,500 shares of Calithera Biosciences or 0.04% of their fund’s portfolio. In addition, Adage Capital Partners Gp L.L.C. have 0.03% of their fund’s portfolio invested in the company for 3.14M shares. The New York-based fund Amici Capital Llc disclosed it had acquired a stake worth about 0.01% of the investment professional’s stock portfolio in Calithera Biosciences. The Texas-based fund Bridgeway Capital Management Inc is also positive about the stock, possessing 6,360 shares or 0.01% of their fund’s portfolio.

Calithera Biosciences (NASDAQ:CALA) Profile

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Calithera Biosciences (NASDAQ:CALA) traded up 2.40% on 28 March, hitting $10.65. A total of shares of the company’s stock traded hands. This is down from average of 1.02 million shares. Calithera Biosciences has a 52 week low of $2.20 and a 52 week high of $14.9. The company has a market cap of $306.15 million and a P/E ratio of 0.

Get the latest Calithera Biosciences (NASDAQ:CALA) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Equity Analysts at H.C. Wainwright Reconfirmed their Buy rating for Calithera Biosciences (NASDAQ:CALA). The TP is Set to $14.0 appeared first on Octafinance.